Conference
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
Authors
Wilson M; Dhani NC; Hirte HW; Welch S; Steed H; Martin LP; Lheureux S; Martin-Lorente C; Mackay H; Butler MO
Volume
32
Pagination
pp. tps5629-tps5629
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.tps5629
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X